Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0GBZYP |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-CD70 antibody |
|||||
| Antigen Name | CD70 |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
PRO1160 [Phase 1/2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have confirmed metastatic/unresectable RCC, NPC, or NHL (stage III/IV), be refractory to prior therapies, have ECOG 0-1, and measurable disease. Exclusions include previous anti-CD70 therapy, active CNS metastases (unless treated/stable), uncontrolled infections, HBV/HCV/HIV positivity, or recent strong CYP3A inhibitor use (dose escalation only).
Click to Show/Hide
|
||||
| Administration Dosage |
PRO1160 monotherapy in escalating doses in Part A and at the recommended phase 2 dose in Part B
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05721222 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description |
Phase 1/2 Study of PRO1160 in Patients With Renal Cell Carcinoma (RCC), Nasopharyngeal Carcinoma (NPC), or Non-Hodgkin Lymphoma (NHL)
|
||||
| Primary Endpoint |
Safety will be evaluated by assessing treatment-emergent adverse events (frequency, severity, and seriousness) and dose-limiting toxicities throughout the treatment period up to approximately 1 year.
|
||||
| Other Endpoint |
Efficacy measurements include objective response rate, disease control rate (assessed by RECIST v1.1 for solid tumors or Lugano 2014 for NHL), progression-free survival (analyzed up to 18 months), and duration of response (tracked until disease progression/withdrawal). Pharmacokinetic analysis will determine PRO1160's peak plasma concentration (Cmax).
Click to Show/Hide
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05721222 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
Phase 1/2 study of PRO1160 in patients with renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), or non-Hodgkin lymphoma (NHL).
|
||||
References